Prise en charge thérapeutique des cancers colorectaux métastatiques au-delà de la deuxième ligne

David Malka; Astrid Lièvre; Romain Coriat; Gérard Lledo; Jaafar Bennouna

doi:10.1684/hpg.2019.1758

Prise en charge thérapeutique des cancers colorectaux métastatiques au-delà de la deuxième ligne

Translated title of the contribution: Therapeutic management of metastatic colorectal cancer beyond the second-line

David Malka, Astrid Lièvre, Romain Coriat, Gérard Lledo, Jaafar Bennouna

Research output: Contribution to journal › Review article › peer-review

Abstract

The improved survival of patients with metastatic colorectal cancer has led to an increasing number of patients able to receive third-line chemotherapy. In this situation, two orally administered drugs, regorafenib and trifluridine/ tipiracil, have become therapeutic standards after having demonstrated a survival improvement as compared to best supportive care in randomised controlled trials. This review article presents the pharmacokinetic, efficacy and safety data for these two drugs, as well as current data on the search for predictive biomarkers of their efficacy, and other treatment options beyond the second line.

Translated title of the contribution	Therapeutic management of metastatic colorectal cancer beyond the second-line
Original language	French
Pages (from-to)	283-293
Number of pages	11
Journal	Hepato-Gastro et Oncologie Digestive
Volume	26
Issue number	3
DOIs	https://doi.org/10.1684/hpg.2019.1758
State	Published - Mar 2019
Externally published	Yes

Bibliographical note

Publisher Copyright:
© John Libbey Eurotext, 2019

Keywords

Colorectal cancer
Metastasis
Regorafenib
Trifluridine/tipiracil

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1684/hpg.2019.1758

Cite this

@article{002115497b64482bb480fd6d5c5c71b0,

title = "Prise en charge th{\'e}rapeutique des cancers colorectaux m{\'e}tastatiques au-del{\`a} de la deuxi{\`e}me ligne",

abstract = "The improved survival of patients with metastatic colorectal cancer has led to an increasing number of patients able to receive third-line chemotherapy. In this situation, two orally administered drugs, regorafenib and trifluridine/ tipiracil, have become therapeutic standards after having demonstrated a survival improvement as compared to best supportive care in randomised controlled trials. This review article presents the pharmacokinetic, efficacy and safety data for these two drugs, as well as current data on the search for predictive biomarkers of their efficacy, and other treatment options beyond the second line.",

keywords = "Colorectal cancer, Metastasis, Regorafenib, Trifluridine/tipiracil",

author = "David Malka and Astrid Li{\`e}vre and Romain Coriat and G{\'e}rard Lledo and Jaafar Bennouna",

note = "Publisher Copyright: {\textcopyright} John Libbey Eurotext, 2019",

year = "2019",

month = mar,

doi = "10.1684/hpg.2019.1758",

language = "צרפתית",

volume = "26",

pages = "283--293",

journal = "Hepato-Gastro et Oncologie Digestive",

issn = "2115-3310",

publisher = "John Libbey Eurotext",

number = "3",

}

TY - JOUR

T1 - Prise en charge thérapeutique des cancers colorectaux métastatiques au-delà de la deuxième ligne

AU - Malka, David

AU - Lièvre, Astrid

AU - Coriat, Romain

AU - Lledo, Gérard

AU - Bennouna, Jaafar

N1 - Publisher Copyright: © John Libbey Eurotext, 2019

PY - 2019/3

Y1 - 2019/3

N2 - The improved survival of patients with metastatic colorectal cancer has led to an increasing number of patients able to receive third-line chemotherapy. In this situation, two orally administered drugs, regorafenib and trifluridine/ tipiracil, have become therapeutic standards after having demonstrated a survival improvement as compared to best supportive care in randomised controlled trials. This review article presents the pharmacokinetic, efficacy and safety data for these two drugs, as well as current data on the search for predictive biomarkers of their efficacy, and other treatment options beyond the second line.

AB - The improved survival of patients with metastatic colorectal cancer has led to an increasing number of patients able to receive third-line chemotherapy. In this situation, two orally administered drugs, regorafenib and trifluridine/ tipiracil, have become therapeutic standards after having demonstrated a survival improvement as compared to best supportive care in randomised controlled trials. This review article presents the pharmacokinetic, efficacy and safety data for these two drugs, as well as current data on the search for predictive biomarkers of their efficacy, and other treatment options beyond the second line.

KW - Colorectal cancer

KW - Metastasis

KW - Regorafenib

KW - Trifluridine/tipiracil

UR - http://www.scopus.com/inward/record.url?scp=85066088436&partnerID=8YFLogxK

U2 - 10.1684/hpg.2019.1758

DO - 10.1684/hpg.2019.1758

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

AN - SCOPUS:85066088436

SN - 2115-3310

VL - 26

SP - 283

EP - 293

JO - Hepato-Gastro et Oncologie Digestive

JF - Hepato-Gastro et Oncologie Digestive

IS - 3

ER -

Prise en charge thérapeutique des cancers colorectaux métastatiques au-delà de la deuxième ligne

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this